Citius Oncology, Inc. CTOR
0.50 USD -0.06 (-10.95%)
Regular-session close
0.50 0.00 0.00%
After hours · Nov 20, 4:00 PM ET
0.502 Day range 0.5698
0.491 52-week range 1.83
- YTD
- -49.65%
- 1 year
- -55.44%
5D -0.0271 (-4.82%)
- Market cap
- 53.25M
- EPS (ttm)
- -0.48
- Shares out
- 71.30M
- YTD return
- -49.65%
- 1-year return
- -55.44%
- 50-day average
- 1.13
- 200-day average
- 7.55
- Volume
- 52.63K
- Avg volume
- 113.40K
- Open
- 0.5698
- Previous close
- 0.5654
- Day's range
- 0.502 – 0.5698
- 52-week range
- 0.491 – 1.83
- Price target
- 3.00 (+495.8%)
Key statistics
- Price / book
- 3.89
- Free cash flow
- 7.11M
- Return on equity
- -85.28%
Fundamental scorecard
3 of 25 checks passed on CTOR’s reported financials
3of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Jun 30, 2026.
Financials — quick view
CTOR Revenue — quarterly 1.49M
CTOR Net income — quarterly -8.92M
CTOR EPS — quarterly -0.08
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | Maxim Group | init | — | Buy |
| Aug 13, 2024 | EF Hutton | main | Buy | Buy |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
News
Your note
Sign in to keep a note on CTOR — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Yakira Capital Management, Inc. | 0.66% | 15,499 | 15.19K | Sep 29, 2024 |
| Virtu Financial LLC | 0.44% | 10,291 | 10.09K | Sep 29, 2024 |
| Osaic Holdings Inc | 0.23% | 5,480 | 5.37K | Sep 29, 2024 |
| UBS Group AG | 0.07% | 1,632 | 1.60K | Sep 29, 2024 |
| Bank of America Corporation | 0.01% | 160 | 156 | Sep 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.00% | 41 | 40 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.10% | 2,332 | 2.29K | Oct 30, 2024 |
